Country: Israel
Language: English
Source: Ministry of Health
HYALURONIC ACID AS SODIUM
GEM PHARMA LTD
S01KA01
EYE DROPS, SOLUTION
HYALURONIC ACID AS SODIUM 0.15 MG/ML
OCULAR
Not required
PHARMA STULLN GMBH, GERMANY
HYALURONIC ACID
HYALURONIC ACID
Symptomatic treatment of dry eye syndrome.
2021-12-09
PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACIST’S REGULATIONS (PREPARATIONS) 1986 The medicine is dispensed without a doctor's prescription EYECON Eye drops Sterile solution without a preservative COMPOSITION: the active ingredient and its quantity: Sodium Hyaluronate 0.15 mg/ml INACTIVE INGREDIENTS: see section 6: "Additional Information". READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THIS MEDICINE. This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor or the pharmacist. This medicine is intended for adults (over 18 years old). You should use the medicine according to the instructions given in the dosage section of this leaflet. Consult with the pharmacist if you need further information. Consult with the doctor if your dry eye symptoms get worse. 1. WHAT IS THIS MEDICINE INTENDED FOR ? Eyecon is intended for treating symptoms of eye dryness (dry eye syndrome). THERAPEUTIC GROUP: eye lubricants. 2. BEFORE USING THIS MEDICINE SPECIAL WARNINGS REGARDING THE USE OF THE MEDICINE BEFORE USING EYECON, TELL THE DOCTOR: - If you have or have ever had impaired eye function (such as glaucoma). There are no studies of the effect of Eyecon on intraocular pressure or effects on its measurement. DO NOT USE EYECON: - If you are sensitive (allergic) to the active ingredient or to any of the other ingredients of this medicine. - In cases where there is an increased risk of internal or external inflammation of the eye (for instance after eye surgery or when a patient has a tendency to get inflammations). CHILDREN AND ADOLESCENTS: Eyecon is not recommended for use in children and adolescents under 18 years of age due to lack of clinical experience in this age group. DRUG INTERACTIONS: IF YOU ARE TAKING OR HAVE RECENTLY TAKEN, OTHER MEDICINES INCLUDING NONPRESCRIPTION MEDICINES AND NUTRITIONAL SUPPLEMENTS, TELL THE DOCTOR OR PHARMACIST. If you are being treated with other eye medicines, wait at least 5 minutes before applying Eyecon eye drops. Eyecon must be the last m Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS (SMPC) 1. NAME OF THE MEDICINAL PRODUCT Eyecon 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: sodium hyaluronate (biotechnologically produced with the help of a natural strain of Streptococcus) For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Eye drop, solution in unit-dose containers 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of dry eye syndrome 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Unless otherwise directed by the doctor, place 4 times a day, 1 drop in the conjunctival sac. The maximum dosage is up to 8 times daily 1 drop. However, various studies showed that more than 4 times daily applications do not lead to further improvement. Eyecon should not be used if there is an increased risk of infection of the inner and outer eye (e.g. after eye operations or in patients susceptible to infections). Eyecon is not recommended for use in children under 18 years of age due to lack of clinical experience. Method of administration Ocular use. If different medication is additionally applied to the eye, then there should be an interval of at least 5 minutes between applications. Always administer Eyecon last. Clinical experience is only available with patients over 18 years of age. 4.3 CONTRAINDICATIONS Hypersensitivity to the active ingredient or to any of the excipients listed in section 6.1. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE No studies regarding the influence of Eyecon on intraocular pressure or its impact on measurement results are available. The contact lenses do not have to be removed during the application if the ophthalmologist approves of contact lens wear for the underlying primary disease. 4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION None known so far. 4.6 FERTILITY, PREGNANCY AND LACTATION No risks were demonstrated by reproduction studies, although controlled studies on pregnant women are not available. 4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES Vi Read the complete document